Clinical Trials Logo

Clinical Trial Summary

The objective is to conduct a pilot study to determine the effectiveness of PURELL VF481 to treat warts located on the hands.


Clinical Trial Description

- At least 5, but not more than 20 participants will be enrolled in the study. - Each wart is randomly assigned a test product prior to the start of the study - Warts are equally distributed between products so that an equal number of warts treated on each person. One (1) product will be assigned to each hand to minimize treatment confusion for the participants - The test product will be applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage. - Subjects will log date and time of application and anything notable (such as changes in wart appearance or missed dose) in a log book. - Measurement of wart (longest diameter) and photos taken at each visit by trained office medical assistants, LPNs, PA-C or MD. - Time points for office visitation: Baseline (0 weeks), 4 weeks, 8 weeks, 12 weeks ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00973856
Study type Interventional
Source Akron General Medical Center
Contact
Status Completed
Phase N/A
Start date September 2009
Completion date January 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05580341 - Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 Phase 3
Recruiting NCT03548740 - Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Completed NCT00092547 - A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Phase 3
Completed NCT00157950 - Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Phase 3
Recruiting NCT00365729 - Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men N/A
Completed NCT03584308 - Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Phase 2
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT04072913 - Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix N/A
Completed NCT00549250 - Human Papillomavirus 6/11 in the Lower Airway of Neonates N/A
Recruiting NCT04694495 - HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
Completed NCT00380367 - Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Phase 3
Completed NCT01894425 - Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation N/A
Completed NCT00685412 - Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3 Phase 1
Completed NCT00365716 - Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Phase 2
Active, not recruiting NCT04772534 - Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) Phase 3
Completed NCT05119855 - Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) Phase 3
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Completed NCT02631863 - Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) Phase 2
Completed NCT01245764 - GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Phase 3
Completed NCT00461877 - High-Risk HPV Infections in Women Aged 25 to 65 N/A